We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) Congress. Baxter also presented eight abstracts that investigated the efficacy of the THERANOVA dialyser.
The abstracts demonstrated that THERANOVA is capable of filtering out mid and large-sized toxins that standard haemodialysis fails to remove from end-stage kidney disease patients. Notably, presence of higher toxins in these patients can affect biological functions and increase cardiovascular risk.
Baxter stated that in-vitro studies have shown that the THERANOVA dialyser is capable of clearing large uremic toxins (such as β-2 microglobulin), much similar to a high-volume hemodiafiltration (HDF) therapy.
Baxter also noted that the THERANOVA dialyser has been designed to work with most standard haemodialysis machines, as compared to the HDF therapy that needs special equipment and ultrapure fluids. THERANOVA’s compatibility with most standard machines significantly lowers treatment cost.
Baxter has received CE marking for THERANOVA in Europe, Australia and New Zealand, among other countries. The company announced that the dialyser will be available in select countries in 2016, with additional launches planned for 2017. The launch will definitely expand Baxter’s in-center haemodialysis portfolio, particularly in international markets.
Meanwhile, the renal division continues to report steady results. In the recently concluded first quarter of 2016, the division reported sales of $898 million, up 5% driven by low double-digit growth in the US Peritoneal Dialysis business. The company sold more than 500 AMIA PD cyclers during the quarter.
Acute business grew nearly 20% driven by increased adoption of extracorporeal therapies, including Continuous Renal Replacement Therapy (CRRT) for acute kidney injuries. Baxter’s Chronic Hemodialysis segment reported low single-digit growth, a positive reversal from the trend witnessed in the year-ago quarter.
Baxter expects the renal product category to exceed $17 billion by 2021, on 6% growth in patient population. Aging population, expanding access in emerging markets and growing adoption of home therapies are the key catalysts.
Zacks Rank & Other Stocks to Consider
Currently, Baxter sports a Zacks Rank #1 (Strong Buy).
Other favorably ranked stocks in the same space include SurModics (SRDX - Free Report) , IRadimed Corporation (IRMD - Free Report) and Masimo Corporation (MASI - Free Report) . All the three stocks sport the same Zacks Rank as Baxter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Baxter International Inc. (BAX - Free Report) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) Congress. Baxter also presented eight abstracts that investigated the efficacy of the THERANOVA dialyser.
The abstracts demonstrated that THERANOVA is capable of filtering out mid and large-sized toxins that standard haemodialysis fails to remove from end-stage kidney disease patients. Notably, presence of higher toxins in these patients can affect biological functions and increase cardiovascular risk.
Baxter stated that in-vitro studies have shown that the THERANOVA dialyser is capable of clearing large uremic toxins (such as β-2 microglobulin), much similar to a high-volume hemodiafiltration (HDF) therapy.
Baxter also noted that the THERANOVA dialyser has been designed to work with most standard haemodialysis machines, as compared to the HDF therapy that needs special equipment and ultrapure fluids. THERANOVA’s compatibility with most standard machines significantly lowers treatment cost.
Baxter has received CE marking for THERANOVA in Europe, Australia and New Zealand, among other countries. The company announced that the dialyser will be available in select countries in 2016, with additional launches planned for 2017. The launch will definitely expand Baxter’s in-center haemodialysis portfolio, particularly in international markets.
Meanwhile, the renal division continues to report steady results. In the recently concluded first quarter of 2016, the division reported sales of $898 million, up 5% driven by low double-digit growth in the US Peritoneal Dialysis business. The company sold more than 500 AMIA PD cyclers during the quarter.
Acute business grew nearly 20% driven by increased adoption of extracorporeal therapies, including Continuous Renal Replacement Therapy (CRRT) for acute kidney injuries. Baxter’s Chronic Hemodialysis segment reported low single-digit growth, a positive reversal from the trend witnessed in the year-ago quarter.
Baxter expects the renal product category to exceed $17 billion by 2021, on 6% growth in patient population. Aging population, expanding access in emerging markets and growing adoption of home therapies are the key catalysts.
Zacks Rank & Other Stocks to Consider
Currently, Baxter sports a Zacks Rank #1 (Strong Buy).
Other favorably ranked stocks in the same space include SurModics (SRDX - Free Report) , IRadimed Corporation (IRMD - Free Report) and Masimo Corporation (MASI - Free Report) . All the three stocks sport the same Zacks Rank as Baxter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>